The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Rates of peripheral neuropathy observed in the POLARIX trial
Marek Trněný, MD, Charles University Hospital, Prague, Czech Republic, provides insight into the rates of peripheral neuropathy observed in the POLARIX trial (NCT03274492) of polatuzumab vedotin plus R-CHP versus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think this is the important question as well because the study, the POLARIX study, which was comparing Polatuzumab-R-CHP versus R-CHOP was positive, but let’s say there is the discussion about the magnitude and the clinical importance of the difference in terms of the progression-free survival and so far we are not able to see any difference in the overall survival...
I think this is the important question as well because the study, the POLARIX study, which was comparing Polatuzumab-R-CHP versus R-CHOP was positive, but let’s say there is the discussion about the magnitude and the clinical importance of the difference in terms of the progression-free survival and so far we are not able to see any difference in the overall survival. So the polyneuropathy question, so it means the adverse effect, the toxicity which patient has to pay to be treated with the therapy is an important issue. And what we have observed, in both arms the peripheral neuropathy rate was almost the same, 52% and only around the 10% have the grade 2 neuropathy and the recovery was similar in both arms. So it means that what we can say is that Polatuzumab vedotin doesn’t increase the peripheral neuropathy incidence if we compare Polatuzumab-R-CHP versus R-CHOP treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
